Immuno-Oncology | Specialty

Stefani Spranger on What Every Oncologist Should Know About Immunotherapy

October 19th 2016

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses the basic knowledge all oncologists should have regarding immunotherapy.

FDA Approves Atezolizumab for Lung Cancer

October 19th 2016

The FDA has approved atezolizumab (Tecentriq) for the treatment of patients with metastatic non–small cell lung cancer who have progressed after a platinum-containing regimen and an FDA-approved targeted therapy for those patients harboring EGFR or ALK abnormalities.

Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLC

October 19th 2016

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non–small cell lung cancer (NSCLC).

Nivolumab/Cabozantinib Combo Shows Promise in GU Cancers

October 18th 2016

Cabozantinib plus nivolumab demonstrated promising activity in the second-line setting and beyond at all dose levels tested in patients with advanced/refractory genitourinary cancers.

Immunotherapy Emerges as Alternative to Surgery in BCG-Refractory Bladder Cancer

October 18th 2016

Surgical treatment of patients with non-muscle invasive bladder cancer can be considered a curative option, but the associated risk in comorbid patients is leading researchers to further explore the option of immunotherapy.

Expert Assesses Immunotherapy Advances in Kidney Cancer

October 18th 2016

Immunotherapy is at the forefront of the burgeoning treatment landscape in renal cell carincoma, according to David McDermott, MD.

Dr. Albiges on Immunotherapy in Renal Cell Carcinoma

October 18th 2016

Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses how immunotherapy has had an impact on the field of renal cell carcinoma (RCC).

Dr. Somlo on Novel Agents in Multiple Myeloma

October 18th 2016

George Somlo, MD, medical oncologist, City of Hope, discusses some of the novel agents being evaluated for the treatment of patients with multiple myeloma.

Immunotherapy Combos, Novel Diagnostics Emerging in Melanoma

October 17th 2016

Jason Luke, MD, discusses some of the exciting research that is happening across the field of immunotherapy in melanoma, including combination strategies, novel agents, and next-generation diagnostics.

Mature Data Sustain Frontline OS Benefit of Pembrolizumab in Melanoma

October 17th 2016

A final analysis of the overall survival data from the KEYNOTE-006 trial showed that frontline pembrolizumab was superior to ipilimumab in the treatment of patients with advanced melanoma.

CHMP Issues Positive Opinion for Nivolumab in Hodgkin Lymphoma

October 14th 2016

The Committee for Medicinal Products for Human Use has recommended approval of nivolumab for the treatment of patients with relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.

Dr. Sabari on Immunotherapy Updates in Small Cell Lung Cancer

October 14th 2016

Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses recent findings in immunotherapy as potential treatment for patients with small cell lung cancer.

Dr. Herbst on Advances of Immunotherapy in Lung Cancer

October 14th 2016

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, associate director for Translational Research, Disease Alligned Research Team Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the current and future impact of immunotherapy in lung cancer.

Researchers Hope to Breathe New Life Into Immunotherapy for Prostate Cancer

October 13th 2016

Since the auspicious 2010 FDA approval of sipuleucel-T as the first immunotherapy vaccine for cancer, advancement with immunotherapy has been slow in the field of prostate cancer.

Dr. Joel Neal on Impact of PD-L1 Tests on Pembrolizumab, Nivolumab Efficacy in Frontline NSCLC

October 12th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses how PD-L1 testing may have played a role in the survival differences between frontline pembrolizumab and nivolumab in non–small-cell lung cancer (NSCLC).

Adding PD-1 Inhibition to Chemotherapy Boosts Response in Untreated NSCLC

October 11th 2016

The addition of pembrolizumab (Keytruda) to frontline platinum-based chemotherapy for advanced non–small cell lung cancer almost doubled the response rate compared with chemotherapy alone.

First-Line Pembrolizumab Shows Substantial Activity in Advanced Bladder Cancer

October 10th 2016

Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity and a favorable response rate.

Nivolumab Misses PFS Endpoint in First-Line Advanced NSCLC

October 10th 2016

First-line therapy with nivolumab failed to improve progression-free survival in PD-L1 positive non-small cell lung cancer compared with standard chemotherapy.

Atezolizumab Significantly Extends Survival in NSCLC

October 10th 2016

Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.

Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval

October 9th 2016

Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.